Aduro Biotech, Inc. , a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on its clinical trials evaluating the LADD immunotherapy platform, enabling patient enrollment to resume in all Aduro-sponsored clinical studies. “We are pleased to come to a rapid agreement with the FDA to resume new patient enrollment in our LADD clinical studies,” said Stephen T. Isaacs, chairman, president and CEO of Aduro Biotech.
